

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 17942

Title: Position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome

Reviewer's code: 02860814

Reviewer's country: Greece

Science editor: Xue-Mei Gong

Date sent for review: 2015-03-31 17:20

Date reviewed: 2015-05-31 17:40

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

1. The author has to refer to other causes of renal deterioration that have to be excluded in these patients, such as volume depletion, nephrotoxic agents, renal parenchymal diseases. 2. The author declares that terlipressin has a few side effects of cardiovascular events. However, everyday clinical practice provides us with different evidence. Those differences probably come from the careful selection of patients without cardiovascular risk in trials with terlipressin. Randomised, controlled trials (Gluud et al, Hepatology 2010) showed that the frequency of severe cardiovascular events in patients treated with vasoconstrictors was of 14%. 3. Superiority of terlipressin from other vasoconstrictor agents (midodrine plus octreotide) should be mentioned (Cavallin, Hepatology 2015). 4. It must be emphasized the need of early recognition/suspicion of this situation and the benefits from the timely and aggressive treatment, even without all the criteria for the diagnosis of HRS met.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 17942

Title: Position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome

Reviewer's code: 00502973

Reviewer's country: China

Science editor: Xue-Mei Gong

Date sent for review: 2015-03-31 17:20

Date reviewed: 2015-05-20 20:27

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In this short review, Sobhonslidsuk et al. summarized the recent advances in the treatment of type 1 hepatorenal syndrome by vasoconstrictor and albumin infusion. It is relevant to the scope of the World Journal of Gastrointestinal Pharmacology and Therapeutics. The English is ok except a few of word expression. 1. "decompensate cirrhosis" change to "decompensated cirrhosis" 2. Page 6, 1st line from the bottom: "a consequence from impaired systolic and diastolic stimuli" change to "a consequence of impaired systolic and diastolic stimuli" 3. Page 7, Line 3: "TREATMENT FOR TYPE 1 HEPATORENAL SYNDROME (HRS)" change to "TREATMENT OF TYPE 1 HEPATORENAL SYNDROME (HRS)" It is acceptable for publication after minor language polish.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 17942

Title: Position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome

Reviewer's code: 00181421

Reviewer's country: Taiwan

Science editor: Xue-Mei Gong

Date sent for review: 2015-03-31 17:20

Date reviewed: 2015-05-24 10:52

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> [Y] Accept
<input checked="" type="checkbox"/> [Y] Grade B: Very good	<input checked="" type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> [] The same title	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> [] Grade C: Good	<input type="checkbox"/> [] Grade C: A great deal of language polishing	<input type="checkbox"/> [] Duplicate publication	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D: Fair	<input type="checkbox"/> [] Grade D: Rejected	<input checked="" type="checkbox"/> [Y] No	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E: Poor		BPG Search:	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> [] The same title	
		<input type="checkbox"/> [] Duplicate publication	
		<input type="checkbox"/> [] Plagiarism	
		<input checked="" type="checkbox"/> [Y] No	

COMMENTS TO AUTHORS

Agree to be published

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 17942

Title: Position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome

Reviewer's code: 02453015

Reviewer's country: United States

Science editor: Xue-Mei Gong

Date sent for review: 2015-03-31 17:20

Date reviewed: 2015-05-26 11:50

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Major comments: 1. English still needs to be improved. 2. An early diagnosis of type 1 HRS is critical to the prognosis. Therefore, what are the criteria for achieving an early diagnosis? 3. Is there any way to start any therapy before reaching diagnostic criteria in order to get a better prognosis?